TLTFF   $0.1695  -13.08% Market Closed

THERALASE TECHS INC
Last Events:

2023-08-04 Signal in Stochastic changed from bearish to bullish. The stochastic indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: signal line crossed the middle level.

2023-08-04 Signal in RSI changed from bullish weakening to bearish. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.

2023-08-04 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-04 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-04 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-07-30 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: down-crossing the middle level.

2023-07-30 Signal in MACD changed from bullish recovery to bullish weakening. Oscillator MACD is in the positive territory it's lower than the signal line and falls. These factors mean that the growing period is over. Last signal: main and signal line crossing.

2023-07-30 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: exit from the overbought zone.


Current temperature: 3.67
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 1
Target Price Mean 0.49
Mean unverified/preliminary 0.49 / 0.49
Target Price Low / High 0.49 / 0.49
Median / STD DEV 0.49 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None None None
rsi Sell Sell Buy
macd None None None
stoch None None None
ma20 None Sell Sell
ma50 None None None
ma100 None Buy None
Candlestick PatternAug. 28, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN CA88337V1004
ceo Mr. Roger John Dumoulin-White B.Sc., P.Eng.
Website https://www.theralase.com
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.